靶向蛋白-蛋白相互作用的抗肿瘤多肽药物的开发与递送  

Development and Delivery of Anti-tumor Peptide Drugs Targeting Protein-Protein Interaction

作　　者：杨文光 高汝青 闫瑾[3] 何旺骁 YANG Wenguang;GAO Ruqing;YAN Jin;HE Wangxiao(Department of Talent Highland,The First Affiliated Hospital of Xi’an Jiaotong University,Xi'an 710061,China;Medical College of Nanchang University,Nanchang 330031,China;National&Local Joint Engineering Research Center of Biodiagnosis and Biotherapy,The Second Affiliated Hospital of Xi’an Jiaotong University,Xi'an 710004,China)

机构地区：[1]西安交通大学第一附属医院人才高地,陕西西安710061 [2]南昌大学医学院,江西南昌330031 [3]西安交通大学第二附属医院国家地方联合生物诊断与治疗中心,陕西西安710004

出　　处：《药学进展》2021年第5期349-362,共14页Progress in Pharmaceutical Sciences

摘　　要：蛋白-蛋白相互作用(PPI)网络异常是肿瘤发生的重要原因。近年来,多肽药物由于其独特的优势被广泛用于靶向肿瘤相关PPI调节剂的开发,并获得了成功。通过对近几年的相关研究进行综述,从靶向PPI多肽的设计与应用角度总结抗肿瘤药物的最新研究进展,以期为基于靶向PPI的抗肿瘤多肽药物研发提供参考。Abnormal protein-protein interaction(PPI)network is an important cause of tumors.Nowadays,a growing number of peptidederived materials have been widely and successfully used due to their unique advantages in the development of modulators targeting tumorrelated PPI regulators.Based on the design and application of peptides targeting PPI,this article summarizes related researches in recent years towards the development of anti-cancer drugs,in an attempt to provide historical reference for their future development.

关 键 词：多肽药物 蛋白-蛋白相互作用 抗肿瘤 药物设计 

分 类 号：R914[医药卫生—药物化学] R943[医药卫生—药学]